Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes. (PROVE-HF)
A 52 Week, Open Label Evaluation of the Effects of Sacubitril/Valsartan (LCZ696) Therapy on Biomarkers, Myocardial Remodeling and Patient-reported Outcomes in Heart Failure With Reduced Left Ventricular Ejection Fraction.
Sponsor: Novartis Pharmaceuticals
A PHASE4 clinical study on Heart Failure, this trial is completed. The trial is conducted by Novartis Pharmaceuticals and has accumulated 17 data snapshots since 2016. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.
Status Flow
Change History
17 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Nov 2021 — Jul 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Nov 2021 [monthly]
Completed PHASE4
▶ Show 12 earlier versions
-
Jan 2020 — Jan 2021 [monthly]
Completed PHASE4
-
Jun 2019 — Jan 2020 [monthly]
Completed PHASE4
-
Apr 2019 — Jun 2019 [monthly]
Completed PHASE4
Status: Recruiting → Completed
-
Nov 2018 — Apr 2019 [monthly]
Recruiting PHASE4
-
Oct 2018 — Nov 2018 [monthly]
Recruiting PHASE4
-
Jul 2018 — Oct 2018 [monthly]
Recruiting PHASE4
-
Jun 2018 — Jul 2018 [monthly]
Recruiting PHASE4
-
Dec 2017 — Jun 2018 [monthly]
Recruiting PHASE4
-
Aug 2017 — Dec 2017 [monthly]
Recruiting PHASE4
-
Apr 2017 — Aug 2017 [monthly]
Recruiting PHASE4
-
Feb 2017 — Apr 2017 [monthly]
Recruiting PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE4
First recorded
Oct 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Novartis Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .